DreaMed Launches its FDA-Cleared Diabetes Management Platform with a Leading U.S. Children’s Hospital

This is the first commercial use of the AI-based Clinical Decision Support System for diabetes since receiving the FDA clearance three weeks ago

DreaMed Diabetes AI LTD. (“DreaMed” or the “Company“), a developer of the Advisor Pro Al Clinical Decision Support platform for diabetes, announced today it deployed its DreaMed’s Advisor Pro – a digital diabetes management platform in one of the top 10 metropolitan U.S. children’s hospital1.

Advisor Pro by DreaMed Diabetes is an Al Clinical Decision Support System for diabetes, providing remote insulin management with data analysis and therapy management tools. The solution was deployed at the hospital together with existing diabetes management protocols so patients can receive a personalized, precise, and effective diabetes treatment.

In the United States alone, 34.2 million people—just over 1 in 10—have diabetes. When it comes to youth diabetes, according to American Diabetes Association, about 210,000 Americans under age 20 are estimated to have been diagnosed with diabetes.

Advisor Pro is the first decision support system to receive FDA clearances for Type 1 and Type 2 diabetes treatments – for pediatrics and adults. The solution leverages AI to optimize insulin administration and assist healthcare providers in caring for diabetes patients who use insulin pumps or injections and monitor their glucose.

“I am thrilled to see DreaMed being used by providers and patients so soon after the recent FDA clearance,” says Eran Atlas, Founder, and CEO of DreaMed Diabetes. “Our first FDA clearance, which was for our Type 1 insulin pump solution, led to partnerships with leading diabetes treatment centers including Yale-New Haven Health, Texas Children’s Hospital, and the University of Florida.”

“Our fourth FDA clearance for our Type 1 & Type 2 solution on insulin injections opened the door to deeper collaborations with top-tier children’s hospitals to improve their diabetes management program for a much larger portion their paitent pannel. Our goal is to help people of all ages manage their diabetes optimally and achieve sustainable health improvement. I’m truly excited that a growing number of healthcare practitioners and their patients can benefit from our solution.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy